Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Schwartz GG, Szarek M, Bittner VA, Diaz R, et al. J Am Coll Cardiol 2021;78:421-433.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Schwartz GG, Szarek M, Bittner VA, Diaz R, et al. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. J Am Coll Cardiol 2021;78:421-433.
PMID: 34325831